Webinar: Innovate Your Cell Line Development Process

Accelerate DNA to therapeutic product timelines: Innovate your cell line development process

Speed to clinic is a priority during the development of a biopharmaceutical. Consequently, reducing time to GMP manufacture remains a challenge for CHO cell line development workflows. However, the goal of a fast development process must be balanced with requirements for high quality and the maintenance of regulatory compliance. A production cell line used for the manufacture of biopharmaceuticals should be derived from a single-cell progenitor. Accordingly, traditional cell line development workflows often contain two rounds of single-cell cloning, resulting in a lengthy process exceeding 6 months.

In this educational webinar, learn how scientists at FUJIFILM Diosynth Biotechnologies have combined the single-cell deposition, imaging, and productivity screening capability of the Sphere Fluidics’ Cyto-Mine® technology with a plate imaging method to create a novel workflow for the generation of high-quality clonal cell lines with high probability and assurance of monoclonality in a single round of cloning. Our expert speakers will also illustrate how the use of this key technology enabler has reduced timelines from 25 to 10 weeks.

Presenters

Dr. Devika Kalsi
Principal Scientist, MCC Upstream Process Development
FUJIFILM Diosynth Biotechnologies

Dr. Xin Liu
Director, Product Development
Director, Cell & Molecular Biology
Sphere Fluidics